← Back to Search

Virus Therapy

Treatment for Squamous Cell Carcinoma

Phase 1 & 2

Recruiting

Research Sponsored by Sherrif Ibrahim

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

"This trial is testing the effectiveness and safety of a treatment called RP1 for cutaneous Squamous Cell Carcinoma. Up to 12 patients will receive RP1 through injection directly into their skin tumors

Who is the study for?

This trial is for adults over 18 with resectable cutaneous Squamous Cell Carcinoma who haven't had treatment on the target lesion. They should be in good health, have a life expectancy over 2 years, and tumors between 1.0 and 3.0 cm in size that are visible and can be measured.Check my eligibility

What is being tested?

The study tests RP1, an investigational drug given by direct injection into the tumor of patients with Squamous Cell Carcinoma. It aims to evaluate its safety, tolerability, and effectiveness in up to 12 participants.See study design

What are the potential side effects?

While specific side effects for RP1 aren't listed here, similar treatments may cause reactions at the injection site, flu-like symptoms, fatigue, fever or chills.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Evaluate degree of pathologic response at 16 weeks.

Secondary outcome measures

Evaluate presence of disease

Evaluate the duration of response

To estimate the complete response (CR) rate

+1 more

Other outcome measures

Survival rate evaluation

Trial Design

1Treatment groups

Experimental Treatment

Group I: TreatmentExperimental Treatment1 Intervention

Patients will receive RP1 via direct intratumoral (IT) injection into superficial cutaneous solid tumors to assess the safety and tolerability as well efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients with resectable CSCC.

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Sherrif IbrahimLead Sponsor

Catherine VanHooft, HTStudy DirectorRochester Dermatologic Surgery

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals in total are enrolled in this research project?

"Indeed, the information on clinicaltrials.gov affirms that this investigation is actively seeking suitable participants. The trial was initially disclosed on June 16th, 2023 and saw its latest update on March 22nd, 2024. Enrollment aims to secure a total of 12 patients at one designated site."

Answered by AI